This was the stock's fourth consecutive day of gains.

Explore the latest news on 23andMe as a U.S. judge approves its sale amid privacy concerns and consumer issues.

This was the stock's second consecutive day of losses.

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to buy 23andMe — the genetic testing company ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...

IP litigation lawyers Joe Loy and Matt Hershkowitz discuss claim construction—one of the most important strategic decisions in patent litigation. The article delves into how various courts address ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected to advance at ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

The initial Wall Street estimates for muscle-preserving therapies follow promising mid-stage results from experimental drugs developed by Regeneron and Scholar Rock. Investors are closely watching mid ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.